Last reviewed · How we verify

NCT03971279

Dexamethasone Intravitreal Implant (Ozurdex®) for Recurrent Vogt-Koyanagi-Harada (VKH) Disease Posterior Uveitis

Completed Last updated 26 November 2019
What this trial tests

trial testing Dexamethasone Ophthalmic implant in Posterior Uveitis in 16 participants. Completed in 22 November 2019.

Timeline
1 January 2017
Primary endpoint
22 November 2019
22 November 2019

Quick facts

Lead sponsorBenha University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment16
Start date1 January 2017
Primary completion22 November 2019
Estimated completion22 November 2019
Sites1 location across United Arab Emirates

Drugs / interventions tested

Conditions studied

Sponsor

Benha University

Who can join

18 and older, any sex, with Posterior Uveitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

VKH disease is a vision threatening condition.The investigators consider that ozurdex intravitreal implant is an effective line of treatment in recurrent VKH posterior uveitis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Dexamethasone Ophthalmic implant

Trials testing the same drug.

Other recruiting trials for Posterior Uveitis

Currently open trials in the same condition.

Other Benha University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03971279.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing